Edwards Lifesciences (NYSE:EW) Given New $90.00 Price Target at Truist Financial

Edwards Lifesciences (NYSE:EW) had its target price lifted by Truist Financial from $87.00 to $90.00 in a research report released on Monday morning,Benzinga reports. The firm currently has a hold rating on the medical research company’s stock.

EW has been the topic of several other reports. Stifel Nicolaus lifted their target price on shares of Edwards Lifesciences from $85.00 to $95.00 and gave the stock a “buy” rating in a research note on Friday. William Blair raised shares of Edwards Lifesciences to a “strong-buy” rating in a research note on Friday, July 25th. Evercore ISI lifted their target price on shares of Edwards Lifesciences from $88.00 to $92.00 and gave the stock an “outperform” rating in a research note on Friday. BTIG Research upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 price objective on the stock in a research report on Tuesday, July 29th. Finally, Wall Street Zen lowered Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, September 29th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $91.39.

Edwards Lifesciences Price Performance

EW opened at $83.06 on Monday. The stock’s 50 day simple moving average is $77.62 and its 200 day simple moving average is $77.05. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. Edwards Lifesciences has a 1 year low of $64.89 and a 1 year high of $87.09. The firm has a market cap of $48.76 billion, a price-to-earnings ratio of 11.95, a PEG ratio of 3.97 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period last year, the company earned $0.67 EPS. Edwards Lifesciences’s revenue for the quarter was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. As a group, analysts predict that Edwards Lifesciences will post 2.45 earnings per share for the current year.

Insider Buying and Selling

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the sale, the insider directly owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 1.29% of the company’s stock.

Institutional Trading of Edwards Lifesciences

Several institutional investors have recently made changes to their positions in EW. Econ Financial Services Corp purchased a new position in shares of Edwards Lifesciences in the 2nd quarter worth approximately $889,000. Allspring Global Investments Holdings LLC lifted its stake in shares of Edwards Lifesciences by 0.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock worth $2,170,000 after acquiring an additional 145 shares during the last quarter. Pacific Capital Partners Ltd purchased a new stake in Edwards Lifesciences in the second quarter worth $1,760,000. Czech National Bank increased its stake in Edwards Lifesciences by 5.8% in the second quarter. Czech National Bank now owns 143,385 shares of the medical research company’s stock worth $11,214,000 after purchasing an additional 7,917 shares during the period. Finally, Mirova US LLC increased its stake in Edwards Lifesciences by 56.2% in the second quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company’s stock worth $229,257,000 after purchasing an additional 1,054,301 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.